Noore

Quick links to important sections

Noore

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Noore

Quick Facts About Noore

Property Description
Active ingredient Norethisterone
Form Oral tablet
Pharmacological class Progestogen
General purpose Hormonal support and regulation
Origin Synthetic (19-nortestosterone derivative)

What is Noore? Definition and Pharmacological Classification

Noore is a prescription-only foundational medicine that contains the single active ingredient, Norethisterone, and is primarily classified as a progestogen. This classification means the medicine belongs to the synthetic steroid hormone analog therapeutic class, designed to mimic the actions of the body’s natural hormone, progesterone.

The medicine's identity is defined by its core chemical component, Norethisterone, which is chemically recognized as a potent progestogen and is recognized for its reliable oral activity. As a progestogen, Noore is integral to hormonal therapy, where its controlled introduction helps manage processes typically regulated by female sex hormones. Norethisterone is categorized as a standard hormonal preparation. This classification establishes Norethisterone as a globally recognized hormonal agent.


The Origin and Form of Norethisterone

Norethisterone is a synthetic substance, specifically a derivative of 19-nortestosterone, and is formulated as an oral tablet for administration. This synthetic origin provides a specific molecular structure that offers enhanced stability, a differentiating factor beneficial for consistent oral dosing.

The selection of an oral tablet facilitates a convenient route of administration, making the hormonal component easily deliverable to the system. Furthermore, as a single-ingredient product, it provides a concentrated focus on the progestational activity of Norethisterone alone, which is an essential distinction from combination hormonal preparations that contain additional components, such as estrogens.


General Purpose: Progestational Activity in Hormonal Therapy

The general purpose of Noore is to provide direct progestin support, which is essential for stabilizing and managing specific hormonal balances within the female reproductive system. A typical use scenario involves providing precise hormonal control to manage the endometrium (the uterine lining). The core action is hormonal mimicry, where Norethisterone engages the body's progesterone receptors to exert a specific influence, particularly in processes like endometrial regulation.

This mechanism makes Noore an effective agent for maintaining hormonal equilibrium. Its progestational activity is leveraged to support necessary physiological adjustments, ensuring controlled and predictable effects essential for its role in broader hormonal therapy, without detailing specific conditions or illnesses it is used to treat.

Regulatory References

  1. NIH MedlinePlus Progestin-Only Oral Contraceptives

What side effects are possible with Noore?

Adverse Reaction Scope

The medicine Noore, which contains the progestogen Norethisterone, has an officially documented safety profile structured by system-organ class and frequency of occurrence. These classifications define the risks reported during clinical use.

Category Description
Frequency Classification Common (up to 1 in 10): Headache, nausea, changes in menstrual bleeding (irregular bleeding, spotting), amenorrhoea, and breast tenderness. Uncommon: Changes in body weight, depressive mood. Rare: Hypersensitivity reactions, urticaria.
System-Organ Classes Involved Adverse reactions are documented across the Reproductive System and Breast Disorders, Nervous System Disorders, Gastrointestinal Disorders, Psychiatric Disorders, and Vascular Disorders.
Serious Adverse Reactions Officially documented risks include thromboembolic events (blood clots, such as deep vein thrombosis or pulmonary embolism), severe hepatic impairment (liver disease, jaundice), and serious hypersensitivity reactions (e.g., angioedema).
Population-Specific Constraints Use is contraindicated in individuals with an established history of active Venous Thromboembolism (VTE) or severe hepatic disease where liver function values have not returned to normal, as specified in regulatory documents.
Exposure-Related Patterns Irregular uterine bleeding and spotting are noted by regulators to be more frequent during the initial months of treatment. Amenorrhoea may be a consequence of long-term continuous use.

Resulting Safety Structure

The official safety information establishes a clear framework of risks, primarily detailing common, expected hormonal effects and identifying rare but clinically significant risks.

The safety profile is formally structured by the risk of hormonal effects (primarily common and expected), alongside the documented rare but serious risks impacting the vascular and hepatobiliary systems. Regulatory documents categorize adverse reactions into Common, Uncommon, and Rare frequency tiers, guiding the overall risk assessment as dictated by official labels. Explicit safety restrictions are defined for specific patient populations, particularly those with a history of blood clots or severe liver impairment, indicating conditions where the medicine is officially contraindicated.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation indicates that overdose with Noore (Norethisterone) is generally associated with a low acute toxicity profile and is not expected to cause severe or life-threatening outcomes. The potential manifestations of overdose are typically linked to the drug's hormonal effects.


Documented Overdose Manifestations and Risks

Classification Official Regulatory Wording / Finding
Documented Manifestations Nausea, Vomiting, Breast tenderness, and Vaginal bleeding (breakthrough or withdrawal)
Severity Classification Overdose is generally considered non-serious; low toxicity profile documented
Antidote Information No specific antidote is known

Required Emergency Actions

The regulatory guidance for managing an overdose emphasizes supportive care. If a patient takes more Noore than prescribed, they should contact a doctor or healthcare provider straight away for advice. Treatment is symptomatic and supportive. In cases of a large overdosage seen within four hours of ingestion, procedures such as gastric lavage may be considered.

Urgent medical attention is explicitly required for symptoms that are classified as warning signs for serious adverse events, such as suspected thrombosis (blood clot) or signs of a severe allergic reaction (e.g., swelling of the face or tongue). These mandated actions reinforce the need to seek professional guidance for any unexpected or concerning event following ingestion.

Therapeutic Uses of Noore

Quick Facts

  • Noore is indicated for managing moderate to severe pain.
  • It assists in the temporary relief of certain types of intense discomfort.
  • The medication is used in the context of controlled pain management plans.

Noore is a prescription medication utilized in a healthcare setting to address pain that is classified as moderate to severe. Its use is generally considered when other pain management options have been found to be insufficient or not appropriate for the patient's condition. The medication is an appropriate component of a broader, structured pain management protocol developed by a qualified healthcare professional.

In the therapeutic domain, Noore is primarily administered to provide temporary relief from significant discomfort, such as acute pain following surgical procedures or trauma, as well as for certain needs in oncology and palliative care. Its core function is to modulate the patient's experience of discomfort, supporting improved functioning and capacity for daily activities during treatment. The proper use of the medication should always follow the prescriber's directives and align with established clinical practice.

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Noore (Norethisterone)

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adult women of reproductive age.
Populations for whom use is contraindicated Women who are pregnant or have known or suspected breast cancer. Patients with active liver disease or tumors. Individuals with a history of thromboembolic disorders (e.g., deep vein thrombosis, stroke) or undiagnosed abnormal vaginal bleeding.
Age-related eligibility rules Not indicated for pre-menarcheal girls (children) or the geriatric population (elderly women).
Condition-specific eligibility rules Use requires careful observation in patients with renal dysfunction, cardiac dysfunction, epilepsy, or migraine headaches due to the potential for fluid retention.
Pregnancy and lactation eligibility status Contraindicated during pregnancy. Use is generally not recommended while breastfeeding.

Eligibility Classifications (High-Level)

Category Official Regulatory Classification
Eligibility severity classification Contraindicated (Absolute prohibition) or Requires Careful Observation (Conditional use).

Connection to the overall eligibility profile: Official regulatory documents establish who can and cannot use Noore by explicitly listing absolute contraindications that prohibit use in patients with specific health histories, such as vascular events or certain cancers. Eligibility is further narrowed by age-related exclusions, formally stating that use is not indicated for those outside the adult reproductive age range. For other groups, the label mandates conditional use or careful observation to manage documented risk factors, defining a strictly regulated scope of use.

What should I know about interactions with other medicines?

The official interaction profile of Noore is governed primarily by pharmacokinetic interactions that alter the drug's systemic exposure. Co-administration with certain medicinal products can significantly affect Norethisterone plasma concentrations through the Cytochrome P450 3A4 (CYP3A4) enzyme system.

Substances that induce the CYP3A4 enzyme, such as certain anticonvulsants (e.g., Phenytoin, Carbamazepine), the antibiotic Rifampicin, and the herbal product St. John's wort, are documented to decrease Norethisterone levels, which may necessitate regulatory guidance on managing efficacy risk. Conversely, strong inhibitors of CYP3A4, including specific antifungals (e.g., Itraconazole, Ketoconazole) or Grapefruit juice, can increase the systemic exposure of Norethisterone.

Pharmacodynamic interactions are also officially noted, including the documented interference between Norethisterone-containing products and Ulipristal acetate, which requires a mandatory administration interval of at least five days. Co-administration with drugs that cause fluid retention may result in an additive pharmacodynamic effect.

Regulatory restrictions classify certain combinations as contraindicated, notably with specific antiviral agents (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) due to potential liver enzyme concerns. Furthermore, the official label prohibits use in patients with markedly impaired liver function due to high risk associated with the drug’s extensive hepatic metabolism.

Mechanism of Action

Alpha-2 Receptor Agonism in the Central Nervous System

Noore works by directly engaging with alpha-2 adrenergic receptors (alpha2-AR) in the brain, acting as an agonist to stimulate their activity. This binding event triggers a G-protein coupled cascade that leads to the inhibition of adenylyl cyclase, resulting in a decrease in intracellular cAMP levels. This action modulates the noradrenergic system, particularly by influencing the neurons of the locus coeruleus ( LC).


Modulation of Noradrenergic Efferent Pathways

By activating the alpha2-AR, the drug initiates a signaling cascade that decreases the release of the neurotransmitter norepinephrine ( NE), which is central to arousal pathways. This reduction in NE flow decreases noradrenergic signaling across wide-ranging efferent projections. This action results in a quantifiable change in the central nervous system's baseline excitability and sympathetic outflow.

Dosage and Administration Information

How to Use Noore

Noore (Norethisterone) is administered exclusively via the oral route as a solid tablet and is intended for use under specific cyclic or continuous protocols. The medicine is taken by mouth and may be administered with or without food.


Official Dosing and Scheduling

Administration schedules are determined by the intended therapeutic goal, leading to varied dose ranges and durations:

Usage Context Typical Daily Dosing Regimen Duration Pattern
Secondary Amenorrhea / Abnormal Bleeding 2.5 mg to 10 mg once daily Short-term cyclic use for 5 to 10 days
Endometriosis Initial 5 mg daily, escalating up to 15 mg maximum daily Continuous use for 6 to 9 months
Menstruation Postponement 15 mg daily, typically divided into three daily doses Temporary use for up to 14 days

Administration Requirements

For continuous dosing regimens, it is essential that the tablet be taken at the same time each day to maintain consistent systemic levels. When used to manage conditions like secondary amenorrhea, the medicine is applied to induce a change in an estrogen-primed endometrium.

In the event of a missed dose (specifically with the low-dose contraceptive formulation) that occurs by more than three hours, the dose should be taken, but a backup non-hormonal contraceptive method must be employed for the following 48 hours to ensure proper use. Following a short course of use, withdrawal bleeding is generally expected to commence within 3 to 7 days after discontinuing the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Noore (Norethisterone)


Evidence for use in Abnormal Uterine Bleeding (AUB) and Heavy Menstruation

Research has been conducted using short-term Randomized Controlled Trials (RCTs) and systematic reviews to explore the characteristics of treatment regimens involving Norethisterone for abnormal or heavy uterine bleeding (AUB/HMB). These studies focused on women of reproductive age who presented with bleeding that lacked a structural cause. The trials often monitored outcomes such as the cessation of acute bleeding episodes and changes in the measured volume of blood loss over defined time intervals.

Findings from these research scenarios describe patterns observed where researchers monitored measurements related to the timing of acute bleeding cessation when higher-dose regimens were used. Comparative evidence suggests that Norethisterone was evaluated alongside other progestogens or standard hormonal treatments, with data showing patterns related to measured changes in bleeding frequency and cycle markers over short follow-up periods. These studies help show what has been observed so far in these research contexts.

However, the evidence is not uniformly robust across all aspects. Follow-up durations were limited in many of the key short-term RCTs that tracked acute episode management. There is limited information for long-term outcomes regarding the sustained tracking of cycle markers or the consistency of cycle stability after treatment is discontinued. Furthermore, while the adoption of standardized diagnostic systems for AUB is improving, some older evidence reflects variability in study protocols, which can make it challenging to directly compare findings across all available research.


Evidence for Endometrial Hyperplasia Management and Prevention

The role of Norethisterone in addressing and exploring outcomes related to changes in the lining of the uterus (the endometrium) has been explored through long-term observational studies and comprehensive systematic reviews of Hormone Therapy (HT) trials. These studies primarily focused on postmenopausal women with an intact uterus who were receiving an estrogen component. Research examined the histological status of the endometrium, which is a key outcome for conditions associated with excessive uterine lining growth.

The evidence describes a consistent pattern related to tracking the histological status of the endometrium when Norethisterone is combined with estrogen. Findings from these research scenarios described in the studies report that the inclusion of the progestogen was associated with researchers monitoring the tracking of endometrial histology status. The research also explored outcomes related to avoiding excessive proliferative changes. This body of research contributes to the broader evidence landscape supporting its use in HT.

Certainty remains low for isolating the effect of Norethisterone entirely, as the vast majority of high-level evidence is derived from studies of combination HT products. Data for certain groups remain insufficient when attempting to define the absolute lowest dose required for tracking endometrial health outcomes without the influence of other hormonal components. Follow-up durations were limited in some shorter studies, although comprehensive reviews often pool data from studies tracking outcomes over several years.


Evidence for Endometriosis

Clinical trials and prospective studies was studied for treatment regimens involving Norethisterone in women with endometriosis. These trials focused on women of reproductive age, particularly those with pelvic or colorectal involvement. Studies explored patient-reported outcomes describing perceived discomfort, including outcomes related to physical discomfort (such as chronic pelvic pain and painful intercourse). Changes in the size of endometriotic lesions was observed in some imaging studies.

Studies reported measurements where pain scores registered variations during the observation period. Comparative research, often involving other hormonal agents, described that outcomes measured during the study period for the Norethisterone group appears to align with those reported by patients receiving other therapies evaluated in the trials. Specific reports noted measured reductions in the volume of ovarian endometriomas in a subset of participants over the study duration.

A key research limitation is that many influential studies were open-label (participants and researchers knew which treatment was received), which can make it challenging to isolate the specific measurements associated with the regimen compared to an inert placebo. Subgroup findings are uncertain for specific manifestations of the condition, as research often focuses on overall pelvic pain. Furthermore, while many studies track outcomes over 6 to 12 months, there is limited information for long-term outcomes on the maintenance of symptom tracking or the prevention of recurrence after treatment cessation.


Evidence for Temporary Menstruation Postponement

Prospective intervention studies and controlled trials have been conducted on healthy women with regular menstrual cycles, research exploring short-term symptom changes related to the temporary alteration of the menstrual cycle. Studies monitored the ability to temporarily delay the onset of a period and tracked the timing of the subsequent return of the cycle. They also examined whether participants experienced episodic or acute changes such as breakthrough bleeding while using the medication.

Research describes that studies focusing on episodes where symptoms become more noticeable reported a temporary delay of the expected menstrual period during the treatment window. Findings also indicate that menstruation was observed in some trials to commence a few days after the study period concluded. Furthermore, trial data show patterns related to instances of unscheduled bleeding or spotting during the period of use.

The available research is highly focused on the short-term goal of delay. Sample sizes were modest in some of these intervention studies, and the evidence quality varies across studies regarding a consistent follow-up to track the complete stability of the cycle many months later.


Long-Term Evidence and Durability of Response

This section summarizes what is known and what remains unstudied across all indications regarding outcomes that extend beyond 12 months. Long-term effects are not fully established for all uses, particularly for the sustained tracking of cycle markers related to Abnormal Uterine Bleeding (AUB) when Norethisterone is used alone. While its role in Hormone Therapy (HT) related to endometrial health outcomes against endometrial hyperplasia has been evaluated in cohorts followed for up to five years, the data for other chronic conditions, such as endometriosis, often track outcomes for intermediate durations (e.g., one year). Research highlights that there is limited information for long-term outcomes on the full tracking of symptom markers and the observed rate at which symptoms may return years after discontinuation.


Evidence in Special Populations and Subgroups

Research has primarily focused on women of reproductive or postmenopausal age without major comorbidities. Data for certain groups remain insufficient. For instance, there is limited information for outcomes related to the use of Norethisterone in adolescents who may be experiencing hormonal imbalances. Likewise, the existing evidence base does not consistently describe specific findings or patterns for individuals with multiple co-morbid conditions, as these women are often excluded from or underrepresented in the controlled clinical trials that form the foundation of the research. Therefore, results apply only to the populations studied in the major trials, and extrapolation to other groups is not supported by dedicated research.


What is Still Uncertain about Noore's Research Base

The overall research provides insight into short-term changes and group patterns. However, evidence quality varies across studies, and certainty remains low in several areas. Key limitations include the need for more large-scale, high-quality, placebo-controlled trials for non-acute, long-term indications like endometriosis, as many existing studies use other active treatments as comparators. Comparative evidence is lacking for some of the common uses, making it challenging to precisely compare Norethisterone to every available treatment in trials. Finally, long-term effects are not fully established regarding the tracking of symptom markers and the prevention of recurrence years after treatment ends across all approved uses. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Noore (FAQ)


Q: Does Noore cause long-term side effects?

The official safety profile documents common short-term effects and rare, serious risks like thromboembolic events (blood clots). Regulatory documents advise that the use of hormonal agents over the long term is a factor considered in patient risk assessment. The official profile provides a basis for the considerations necessary during continuous use.


Q: How quickly should I expect to see an effect from Noore?

The timing of observed changes varies depending on the medical purpose. According to official product information, for the temporary postponement of menstruation, the medicine is taken to be effective at the start of the course. For conditions like secondary amenorrhea, a change, known as withdrawal bleeding, is generally observed to begin 3 to 7 days after the medicine is stopped.


Q: Does Noore interact with common over-the-counter pain relievers?

Official regulatory documents focus primarily on major interactions with specific drug classes, such as certain antibiotics and anti-seizure medicines. Common over-the-counter pain relievers are generally not listed as major interactions that require mandatory avoidance or dose changes. It is important to disclose all medicines and products being used to a healthcare professional.


Q: Can Noore be taken at the same time as cold or allergy medicine?

Regulatory interaction profiles focus on drugs that can significantly alter the body's breakdown of Noore. Specific common cold and allergy medicines are not typically listed as having major, contraindicated interactions in core regulatory documents. However, all other medicines, including over-the-counter products, should be discussed with a healthcare professional.


Q: What happens if I forget to take a dose of Noore?

For therapeutic use of Noore, if a dose is forgotten, the general guidance in patient information is to take the missed dose as soon as it is remembered. The subsequent scheduled dose is generally taken at the usual time. Regulatory guidance indicates avoiding the taking of two doses at once to compensate for the forgotten dose.


Q: Can Noore cause weight changes?

Official safety documents describe changes in body weight as an uncommon side effect of Noore. This means the effect may occur in up to 1 in 100 people who use the medicine.


Q: What kind of monitoring is usually required when taking Noore?

Official guidance indicates that considerations for monitoring may include regular blood pressure monitoring and assessment of menstrual patterns. Additionally, liver function tests may be considered periodically, especially when using higher therapeutic doses of the medicine.


Q: Does Noore cause problems with pregnancy or breastfeeding, according to official documents?

Official regulatory documents state that Noore is contraindicated (absolutely prohibited) during pregnancy. Use is also generally not recommended while breastfeeding. The official guidance states that the risks versus benefits should be a consideration regarding use during lactation.


Q: What is the percentage of people who experience common side effects with Noore?

The official frequency classification for side effects defines Common as those effects that may occur in up to 1 in 10 people who use the medicine.


Q: How long does one dose of Noore stay in the body?

Pharmacokinetic studies—which examine how the body processes the medicine—indicate that the elimination half-life of the active ingredient, Norethisterone, typically ranges from 5 to 13 hours. The half-life is the time it takes for half of the dose to be cleared from the system.


Q: What are the signs of a potential overdose of Noore?

Official labeling states that overdosage is generally not expected to be dangerous and may primarily cause symptoms such as nausea, vomiting, and/or withdrawal bleeding. Regulatory documents indicate that medical evaluation may be considered if a large dose is taken.


Q: Does Noore contain lactose or gluten?

Official labeling for some formulations of Norethindrone tablets lists lactose as an inactive ingredient. Patients should be aware of this if they have a diagnosed lactose intolerance. The presence of gluten is generally not specified on the primary label.


Q: Does Noore affect the ability to drive or operate machinery?

Official documents state that Noore is not known to directly affect the ability to drive or use machines. If dizziness or lightheadedness occurs, official documents advise exercising caution when driving or operating machinery.


Q: Are there any major diet changes required when using Noore?

Official regulatory documents note a major interaction with Grapefruit juice, which may increase the blood levels of the medicine. It is advised to limit or avoid consumption of Grapefruit juice. No other specific diet changes are generally noted for all uses in the official labeling.


Q: Can Noore be taken by people with diabetes?

Regulatory documents advise that patients with diabetes may require careful observation when using Noore. Progestin therapy can potentially influence carbohydrate metabolism, and official guidance suggests that monitoring may be considered.


Q: What is the recommended age range for using Noore?

Official eligibility rules state that the medicine is not indicated for pre-menarcheal girls (children) or the geriatric population (elderly women). Its use is primarily intended for adult women of reproductive age.


Q: Does Noore cause dizziness or lightheadedness?

Official safety profiles list dizziness as a possible side effect, usually classified under Central Nervous System disorders. The frequency of this side effect is typically not categorized as common. If dizziness occurs, caution should be exercised.


Q: Why do some people say they feel tired when they start taking Noore?

Official safety profiles classify fatigue (tiredness) as a possible side effect. This is usually listed under Central Nervous System disorders in regulatory documents, although the frequency of this side effect is typically not categorized as common in the official profile.


Q: Is it true that Noore can affect sleep patterns?

Official safety profiles list insomnia (trouble sleeping) as a possible side effect of the medicine. This is included under Central Nervous System disorders, and the official profile lists insomnia as a possible effect.


Q: Does Noore interfere with laboratory test results?

Official regulatory information describes that progestogens can influence the results of certain laboratory tests. This may specifically include tests for hepatic function (liver), thyroid function, and coagulation (blood clotting). Patients should inform laboratory personnel that they are taking this medicine.


Q: Are there any lifestyle changes that official sources suggest when taking Noore?

Official labeling advises patients using Noore for contraception to avoid smoking as it greatly increases the risk of serious side effects like blood clots while taking hormonal contraception. No other specific lifestyle changes are generally noted for all uses in the official labeling.


Q: How does Noore affect blood pressure?

Regulatory documents advise that the medicine may cause a significant increase in blood pressure. Blood pressure monitoring is recommended during the course of use. If a notable or persistent increase in blood pressure occurs, the medicine may need to be considered for discontinuation pending further examination.


Q: Can teenagers use Noore?

Official eligibility documents state the drug is not indicated for pre-menarcheal girls (children). Use in adolescents (post-menarcheal teenagers) is generally left to the clinical assessment of a healthcare professional. The drug's primary population is defined as adult women of reproductive age.

How should Noore be stored and disposed of?

The official storage and disposal guidelines for Noore are established to maintain the medicine's integrity and ensure public safety.

Storage Conditions and Handling

Noore tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), and must not exceed 25 C. The medicine must be kept in its original container and protected from light. Due to safety requirements, it is mandatory to store Noore out of the sight and reach of children and in a location inaccessible to others.

Disposal Instructions

Unused or expired Noore should be disposed of promptly. The preferred method is through an authorized drug take-back location or by using any prepaid mail-back envelopes provided. If neither is available, the product must be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. The medicine must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Noore found in:

A-Z Index: